← Eichor
Condition: Docetaxel Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Docetaxel

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patien
Phase 2/Phase 3 · 2 location(s) · Shanghai Jiao Tong University School of Medicine · NCT03258320A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination Wi
Phase 2/Phase 3 · 1 location(s) · Shanghai Henlius Biotech · NCT07459751ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Phase 3 · 152 location(s) · OncoC4, Inc. · NCT05671510Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma
Phase 2 · 5 location(s) · Centre Hospitalier Universitaire de Besancon · NCT04894370Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative
Phase 2 · 3 location(s) · City of Hope Medical Center · NCT06042569Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07528274Auricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07537699The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer
Phase N/A · 2 location(s) · Uppsala University · NCT06446401A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1 · 11 location(s) · Kyowa Kirin Co., Ltd. · NCT06266299Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Mon
Phase 3 · 36 location(s) · ImmunityBio, Inc. · NCT06745908Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastri
Phase 2 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT06947291Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
Phase N/A · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT06947668A Phase I Study of SIM0388 in Participants With Malignant Ascites.
Phase 1 · 1 location(s) · Jiangsu Simcere Pharmaceutical Co., Ltd. · NCT07007988TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05901428WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07330050Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Ste
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT07662018Neoadjuvant Nivolumab, Docetaxel, Cisplatin Therapy Followed by Surgery and Radiation Therapy for Resectable High Grade
Phase 2 · 1 location(s) · Myung-Ju Ahn · NCT05727410Docetaxel, Oxaliplatin and 5-FU for Gastric Cancer With Inoperable Malignant Bowel Obstruction
Phase 2 · 1 location(s) · Sixth Affiliated Hospital, Sun Yat-sen University · NCT04840264Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage
Phase 2 · 1 location(s) · Shanghai Jiao Tong University School of Medicine · NCT02290145A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/Phase 2 · 20 location(s) · Hummingbird Bioscience · NCT05910827Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI
Phase 1/Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT05381038Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer
NA · 1 location(s) · Centre Henri Becquerel · NCT05858398A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants Wit
Phase 3 · 281 location(s) · Celgene · NCT06764485Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Phase 2 · 1 location(s) · Christopher Wilke · NCT02128906Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
NA · 1 location(s) · Qilu Hospital of Shandong University · NCT07172685Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
Phase 1/Phase 2 · 1 location(s) · Rigshospitalet, Denmark · NCT06480110Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy
NA · 1 location(s) · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · NCT07558447Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
Phase 2 · 1 location(s) · Erasmus Medical Center · NCT05762536A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic
Phase 3 · 144 location(s) · Amgen · NCT07213674Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and
Phase 2 · 1 location(s) · Shengjing Hospital · NCT05638594
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.